Modern pharmacological studies have shown that binding with some receptors and (or) channels and (or) enzymes on cell membranes or inside cells is the key step of carrying out drug bioactivities. This combination process could directly elucidate the mechanisms of interaction between bioactive compounds and targets at the level of molecule and cell. Based on this principle, our group proposed the method of live cell extraction coupled with HPLC-MS analysis to predict bioactive components in HMs. [5] [6] [7] However, the previous work was concerned with the single active cell, we established a multiple-cell screening method to predict the bioactive components generally according to the multiple targets with multi-activities. The hypothesis is when cells are incubated with the extract of HMs, the potential bioactive compounds in HMs should selectively combine with the cells, and the cell-combined components would be detectable in the extract of denatured cells. So far as we know, it is widely accepted that multiple constituents, which manifested bioactivity on multiple acting sites, are the material basis of the therapeutic effects of HMs. Therefore, multiple target cells were simultaneously applied in our experiment together with the high performance liquid chromatography coupled with diode array detection-mass spectrometry (HPLC-DAD-MS) analysis.
Radix Salviae miltiorrhizae (RSM), Danshen in Chinese, is a commonly used HM for improving body function, e.g. promoting circulation and improving blood flow. 8, 9) Pharmacological researches revealed that RSM has many bioactive effects, such as suppressing tumor necrosis factor-a-induced intercellular cell adhesion molecule-1 and vascular adhesion molecule-1 expression in human umbilical vein endothelial cells, 10) protecting myocardial damage, 11) inhibiting platelet aggregation 12) and protecting the red cell membranes of rabbits in inflammation. 13) However, what are the exact bioactive compounds in RSM to be responsible for those pharmacological effects are still not clearly known. Based on the corresponding pharmacological reports, four types of target cells, i.e. endothelial cells, myocardial cells, blood platelets and red cells, were chosen in this study, with the purpose of screening the bioactive components of HMs, comparing the absorption results of different target cells, and predicting the possible reasons for the differences.
MATERIALS AND METHODS
Herbal Materials and Chemicals RSM were purchased from Shanxi Tasly Plants Pharmaceutical Co., Ltd. (Shangluo City, Shanxi Province, China). Reference compounds, i.e. danshensu, protocatechuic aldehyde, salvianolic acid B, were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, P. R. China); tanshinone I, methylene tanshiqunone and dihydrotanshinone I were purchased from Sikehua biotechnology Co., Ltd. (Chengdu, P. R. China); rosmarinic acid was purchased from Kangjiu chemical engineering Co., Ltd. (Shanghai, P. R. China). Blood platelets and red cells were purchased from Jiangsu province blood center. HPLC grade acetonitrile was purchased from Merck Company (Merck, Darmstadt, Germany); deionized water was purified by Milli-Q system (Millipore, Bedford, MA, U.S.A.). All other chemicals were analytical grade. All solvents and samples were filtered through 0.45 mm membranes before injecting into HPLC for analysis.
Extraction of Chemical Constituents from RSM Ten gram powders of RSM were refluxed in 90% EtOH of 60 ml and extracted 1 h for twice. Then the residue was refluxed in 70 ml water and extracted 1 h for twice successively. 14) Each extraction was filtered, combined. And then, the solvent was removed with rotary evaporation at 40°C under vacuum. The residue was freeze-dried to dryness and yield is 24.9% (nϭ3). The powders of RSM extraction were weighted and dissolved in 0.9% sodium chloride buffer containing 0.1% polysorbate-80 (SCP, pH 7.2) and filtered through a 0.22 mm membrane. The filtrate was used as a sample for further experiments.
Cell Culture Myocardial cells were obtained from pathogen-free neonate rat of both sexes. The university Animal Care committee approved all protocols. Cardiac ventricles were removed, placed in ice-cold Ca 2ϩ -and Mg 2ϩ -free phosphate buffer solution and cut into 1-2-mm pieces. Tissue was dissociated into single cells by repeated incubation with 10 ml of 0.08% trypsin at 37°C for 10 min with stirring. The supernatant from the first digestion was discarded and subsequent supernatants collected at 10-min intervals and combined with an equal volume of Dulbecco's modified Eagle's medium (DMEM) containing 20% fetal bovine serum (FBS), 10 mg l Ϫ1 basic fibroblast growth factor (bFGF), 100 kU l Ϫ1 penicillin (Sigma) and 100 mg l Ϫ1 streptomycin sulphate (Sigma). After centrifugation at 1000ϫg for 10 min, the cell pellet was resuspended in DMEM and plated in clear-bottom black 96-well plates at a final density of approximately 7.0ϫ10 4 cells well Ϫ1 and cultures maintained in a humidified atmosphere of 5% CO 2 -95% air at 37°C in DMEM until reaching confluence (5-6 d after seeding). Endothelial cell culture was described in our previous report.
5) The cells were cultured until reaching confluence (2-3 d after seeding). Then the myocardial cells and endothelial cells were dissociated with 0.08% and 0.125% trypsin, respectively. After centrifugation at 1000ϫg for 3 min, the deposited cells were suspended with SCP (pH 7.2) for live cell extraction. Blood platelets and red cells from blood donor were separated automatically by blood collection machine.
In this experiment, endothelial cells, blood platelets and red cells are obtained from healthy human, while the myocardial cells from rat. Considering the fact that it's hard to get myocardial cells from health human, we chose pathogen-free neonate rats as the source. However, the physiological index of myocardial cells is familiar between human and rat. 15) Cells Extraction Endothelial cells mixed with 2 ml extract of RSM were incubated at 37°C for 1.5 h. The suspension was centrifuged at 1000ϫg for 10 min then the cell precipitate was washed four times to remove the unbound compounds. Each wash was accomplished by addition of 2 ml of SCP (pH 7.2) with subsequent centrifugation at 1000ϫg for 10 min. The eluates were discarded except the last one that was collected as contrast for HPLC-DAD-MS analysis. Finally, the cell precipitate was denatured and extracted with 2 ml of 75% EtOH, then the bound components to cells were released. After centrifugation at 1000ϫg for 10 min, the supernatant was filtered through 0.45 mm membrane for HPLC-DAD-MS analysis. Meanwhile, the control sample of cellcontaining buffer was prepared using the same procedures with the blank buffer described above.
Myocardial cells mixed with 2 ml extract of RSM were incubated at 37°C for 2 h and the rest procedures were analogous to those performed on endothelial cells.
Blood platelets mixed with 2 ml extract of RSM were incubated with shaking for 30 min at 37°C. Except the cells were washed twelve times and denatured with 2 ml of SCP (pH 4), then the desorption eluate from this step is evaporated to dryness by centrifugation in vacuo and reconstituted in 2 ml 75% EtOH immediately before analysis. The rest procedures were analogous to those performed on endothelial cells.
Red cells mixed 2 ml extract of RSM were incubated with shaking for 30 min at 37°C, and the rest procedures were analogous to those performed on blood platelets.
HPLC Analysis Chromatographic analysis was performed on an Agilent Series 1100 liquid chromatograph (Agilent Technologies, Palo Alto, CA, U.S.A.), equipped with a dual pump, a Rheodyne7125i injection valve with a 20 ml sample loop and a DAD detector, data were acquired and processed by an HP ChemStation. A ZORBAX ODS C18 column (4.6 mmϫ250 mm i.d., 5 mm) and a ZORBAX ODS C18 guard column (4.6 mmϫ12.5 mm i.d., 5 mm) were employed, the column temperature was set at 30°C. The mobile phase consisted of (A) 0.1% aqueous formic acid and (B) acetonitrile. The gradient elution conditions applied were: 0-10 min, 7-17% B; 10-12 min, 17-20% B; 12-16 min, 20-21% B; 16-32 min, 21% B; 32-40 min, 21-29% B; 40-55 min, 29-35% B; 55-65 min, 35-65% B; 65-80 min, 65-80% B. The flow-rate was 1 ml min Ϫ1 , and the injection volume was 20 ml. The detection wavelength was set at 281 nm.
The high resolution MS analysis was performed on an Agilent G1969 LC/MSD TOF system (Agilent Technologies) equipped with an ESI source. Data were acquired and analyzed by LC-MS TOF Software Ver. A. 01. 00 (Agilent Technologies) and PE Sciex Analyst QS1.1. The operating conditions for the ESI source were as follows: the capillary temperature, 320°C; capillary voltage, 4000 V; drying gas (N 2 ) flow, 9 l min
Ϫ1
; nebulizer (N 2 ) pressure, 35 pis. Full scan data acquisition was performed from m/z 100 to 3000 in MS scan mode.
RESULTS AND DISCUSSION
The bioactive components of RSM were screened and analyzed by using live cell extraction coupled with HPLC-DAD-MS analysis. At last, fourteen of the totally sixteen bioactive compounds were identified.
Optimizations of the Conditions. Selection of the Buffer Solution The SCP was chosen as the buffer solution for two reasons. Firstly, according to the chemical structures, the major bioactive constituents of RSM could be classified into two groups including water-soluble phenolic acids and lipophilic diterpenoid quinones. And SCP could dissolve both the polar and non-polar compounds of RSM extract. Secondly, sodium chloride shows the similar osmotic pressure of cells with the body fluid. In addition, cells could keep the normal physiological activities in SCP. 16) Incubation of Drug-Containing Buffer Only The incubation of polyphenolic compounds, such as rosmarinic acid, salvianolic acid B in alkaline buffer (pH 7.2) may result in the hydrolysis of ester bond and/or oxidation of the phenolic hydroxyl group. Therefore, HPLC analysis was used for investigating this possibility. The procedures of incubation of drug-containing buffer only were analogous to those performed on cells. Based on the HPLC chromatography, the components of drug were stable in this condition of incubation.
Conditions of Cell Culture It is well known that the drug absorption of the cells plays a very important role in drug-cell interaction. Too high drug concentration will result in cell death due to cytotoxicity of drug, while too low one may render a missing detection. The time of drug-cell interaction should not be neglected, either. 17) In the preliminary experiments, the above two factors were investigated and optimized. Drug concentrations of 5 mg ml Ϫ1 , 10 mg ml Ϫ1 and 15 mg ml Ϫ1 were tested. Toward incubated time of drug-cell, six points (0.5, 1, 2, 4, 6, 8 h) were tested. Taking it into account the results of optimization (data not shown), the conditions of the cell culture proposed were the final concentration of RSM was 10 mg ml Ϫ1 and time for drug-cell treatment were 1.5 h for endothelial cells, 2 h for myocardial cells and 0.5 h for both blood platelets and red cells. By observing under a powerful microscope, the cells were found to keep alive with shapes unchanged in the optimizing incubation time and drug concentration. In addition, blood platelets and red cells were extracted from the blood donor in less than 24 h to ensure their survival.
Conditions of Cell Washing and Digesting Drug-cell incubation mixtures were washed by SCP (pH 7.2) to remove the unbound compounds on the cell surface. The remaining components of the target cells would be of potential bioactivities. As most of the active compounds were in low level, it would be very important to ensure that these compounds binding with cells were well released and the unbound compounds had been washed away completely. Toward denaturing solution, 100% EtOH, 75% EtOH and SCP (pH 4) were tested. Toward times for washing unbound compounds, six points (two, four, six, eight, ten and twelve times) were tested. Taking it into account the results of optimization (data not shown), the times of washing proposed were four times for endothelial cells and myocardial cells, and twelve times for blood platelets and red cells. By observing the treated cells microscopically, 75% EtOH was selected to denature endothelial cells and myocardial cells, and SCP (pH 4) was selected to denature blood platelets and red cells.
Identification of the Bioactive Candidates in RSM Based on the optimized conditions as mentioned above, the wavelength of HPLC-DAD analysis was set at 281 nm for desorption eluates of four types of cells as well as the ten reference compounds, i.e. danshensu, protocatechuic aldehyde, rosmarinic acid, lithospermic acid, salvianolic acid B, dihydrotanshinone I, cryptotanshinone, tanshinone I, methylene tanshiqunone and tanshinone IIA. The clear chromatograms with baseline separations were shown in Fig. 1 . As the results manifested, bioactive compounds in RSM possessed selective interaction with different target cells. Specifically, eleven peaks were detected in the desorption eluate of endothelial cells, nine in myocardial cells, fifteen in blood platelets and five in red cells. However, these peaks were not found in the final washing eluates and eluates of only cell-containing buffer, which suggested that the identified peaks were of the Table 1 in terms of the t R , UV l max , and MS data were shown in Fig. 2. Additionally, Fig. 3 showed the chemical structures of all potential bioactive compounds.
With the comparison of the t R , UV l max , and MS data with those reference compounds, peaks 1, 3, 5, 6, 7, 10, 12, 13, 14 and 15 in the chromatograms of RSM extract were unequivocally identified as danshensu, protocatechuic aldehyde, rosmarinic acid, lithospermic acid, salvianolic acid B, dihydrotanshinone I, cryptotanshinone, tanshinone I, methylene tanshiqunone and tanshinone IIA. Since we are short of the reference compounds, the identifications of the other peaks were mainly achieved by ESI-TOF mass spectrometer which gives the molecular weight with a high accuracy and a relatively low error. With the comparison of the UV and MS data with the published ones, peaks 4, 9, 11 and 16 were tentatively assigned as salvianolic acid D, danshexinkun D, danshexinkun B and miltirone. [18] [19] [20] [21] [22] The identification of peaks 2 and 8 needs further investigation. As is shown by the results, peaks 3, 6-8 and 10-16 were identified in the desorption eluate of endothelial cells, and peaks 7, 8 and 10-16 
Analysis of the Compounds Interacting with Target Cells
As discussed above, most tanshinones and salvianolic acid B were detected as major bioactive candidates. It has been reported that tanshinones have diverse biological activities, such as anti-thrombus and anti-platelet aggregatory activities. 23) Moreover, tanshinones may intervene the vasoactive peptides in hypertrophic myocardial tissue so as to reverse ventricular hypertrophy. 24) Based on the pharmacological research, salvianolic acid B not only has the actions described above, but also could reduce atherosclerosis, inhibit low density lipoprotein and improve regional cerebral blood flow. [25] [26] [27] These findings indicate that tanshinones and salvianolic acid B do have bioactivities relevant to efficacy of RSM for cardiovascular disease treatment, and are with high probability the bioactive components of this combined prescription, which accordingly imply that this newly proposed strategy might be a useful approach for rapidly screening and analyzing potential bioactive candidates in HMs.
In the optimization of conditions of cell culture, drug concentration of 5 mg ml Ϫ1 , 10 mg ml Ϫ1 and 15 mg ml Ϫ1 were tested. The combined compounds were the same in different drug concentration, which maybe shows that the compounds were specifically bound to the cells. On the other hand, comparing the screening results of diverse target cells, we found that the amount and the type of the absorbed bioactive compounds interacting with various target cells were quite different. This show that different bioactive components selectively combined with different target cells. We presume that the selectivity is due to the different receptors and (or) channels and (or) enzymes on the four kinds of target cell membranes. And the different structures of bioactive compounds should be another reason for the selectivity. Furthermore, the selectivity results in the different pharmacological actions of different compounds. It is reported that protocatechuic aldehyde and rosmarinic acid have anti-atherosclerosis activity. 28) As is shown from the results, rosmarinic acid was only found in the desorption eluate of blood platelets, while protocatechuic aldehyde was detected in three types of cells: endothelial cells, blood platelets and red cells. Therefore, we could presume that the mechanisms of their activities were different. In addition, lithospermic acid, which might be a bioactive compound with anti-thrombus action, apart from the two types of compounds above, was found in the desorption eluates of both endothelial cells and blood platelets. With respect to the amount of absorbed bioactive compounds, there are fifteen ones detected from the denatured blood platelets, but only five from the red cells.
CONCLUSION
In this study, extraction of four types of target cells coupled with HPLC-DAD-MS analysis was established and successfully applied to the prediction of potential multiple bioactive compounds in the complex HM, RSM in specificity. The results indicated that this newly proposed strategy was in coincidence with the holistic characteristic, multiple constituents and acting sites of HM efficacy. Moreover it might be a useful approach to study the bioactive candidates in HMs with high selectivity and possibility. 
